Golden State Equity Partners Acquires 196 Shares of Chemed Co. (NYSE:CHE)

Golden State Equity Partners lifted its holdings in shares of Chemed Co. (NYSE:CHE) by 29.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 869 shares of the company’s stock after acquiring an additional 196 shares during the quarter. Golden State Equity Partners’ holdings in Chemed were worth $508,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CHE. SG Americas Securities LLC boosted its stake in Chemed by 32.8% in the 3rd quarter. SG Americas Securities LLC now owns 3,290 shares of the company’s stock valued at $1,710,000 after purchasing an additional 813 shares during the period. Trinity Street Asset Management LLP boosted its stake in Chemed by 3.0% in the 3rd quarter. Trinity Street Asset Management LLP now owns 29,861 shares of the company’s stock valued at $15,519,000 after purchasing an additional 863 shares during the period. Xponance Inc. boosted its stake in Chemed by 1.8% in the 3rd quarter. Xponance Inc. now owns 2,974 shares of the company’s stock valued at $1,546,000 after purchasing an additional 54 shares during the period. Raymond James & Associates boosted its stake in Chemed by 2.7% in the 3rd quarter. Raymond James & Associates now owns 64,264 shares of the company’s stock valued at $33,398,000 after purchasing an additional 1,669 shares during the period. Finally, Legacy Financial Group LLC bought a new stake in Chemed in the 3rd quarter valued at $48,000. 95.85% of the stock is currently owned by institutional investors.

Insider Transactions at Chemed

In other Chemed news, EVP Spencer S. Lee sold 2,000 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $641.65, for a total value of $1,283,300.00. Following the completion of the transaction, the executive vice president now owns 20,760 shares of the company’s stock, valued at approximately $13,320,654. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Chemed news, EVP Spencer S. Lee sold 2,000 shares of the company’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $641.65, for a total value of $1,283,300.00. Following the sale, the executive vice president now owns 20,760 shares in the company, valued at approximately $13,320,654. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael D. Witzeman sold 2,650 shares of the company’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $643.14, for a total value of $1,704,321.00. Following the completion of the sale, the chief financial officer now owns 2,882 shares in the company, valued at approximately $1,853,529.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 15,808 shares of company stock valued at $10,184,531. Corporate insiders own 3.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Royal Bank of Canada boosted their price target on Chemed from $604.00 to $712.00 and gave the company an “outperform” rating in a research note on Monday, March 4th. StockNews.com cut Chemed from a “buy” rating to a “hold” rating in a report on Friday. Finally, Oppenheimer lifted their price objective on Chemed from $625.00 to $650.00 and gave the company an “outperform” rating in a report on Thursday, February 29th.

Chemed Trading Down 2.3 %

NYSE CHE traded down $12.92 during midday trading on Friday, hitting $560.42. The company had a trading volume of 102,418 shares, compared to its average volume of 69,274. The company has a market capitalization of $8.47 billion, a PE ratio of 30.16, a P/E/G ratio of 2.30 and a beta of 0.42. The firm has a 50-day moving average price of $623.29 and a 200-day moving average price of $590.84. Chemed Co. has a twelve month low of $492.84 and a twelve month high of $654.62.

Chemed (NYSE:CHE) last posted its quarterly earnings results on Wednesday, April 24th. The company reported $4.68 EPS for the quarter, missing analysts’ consensus estimates of $5.09 by ($0.41). Chemed had a return on equity of 30.52% and a net margin of 12.36%. The business had revenue of $589.23 million for the quarter, compared to analyst estimates of $587.18 million. On average, equities analysts anticipate that Chemed Co. will post 21.99 EPS for the current year.

Chemed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Monday, February 26th were issued a dividend of $0.40 per share. The ex-dividend date of this dividend was Friday, February 23rd. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.29%. Chemed’s dividend payout ratio (DPR) is currently 8.61%.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.